- Home
- CSBR vs ABOS Comparison
CSBR vs ABOS Comparison
Compare CSBR & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSBR
- ABOS
- Stock Information
- Founded
- CSBR 1985
- ABOS 1996
- Country
- CSBR United States
- ABOS United States
- Employees
- CSBR N/A
- ABOS N/A
- Industry
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- CSBR Health Care
- ABOS Health Care
- Exchange
- CSBR Nasdaq
- ABOS Nasdaq
- Market Cap
- CSBR 123.2M
- ABOS 103.6M
- IPO Year
- CSBR 1986
- ABOS 2021
- Fundamental
- Price
- CSBR $6.42
- ABOS $1.71
- Analyst Decision
- CSBR Strong Buy
- ABOS Strong Buy
- Analyst Count
- CSBR 1
- ABOS 3
- Target Price
- CSBR $12.00
- ABOS $8.00
- AVG Volume (30 Days)
- CSBR 40.7K
- ABOS 370.1K
- Earning Date
- CSBR 09-15-2025
- ABOS 11-11-2025
- Dividend Yield
- CSBR N/A
- ABOS N/A
- EPS Growth
- CSBR N/A
- ABOS N/A
- EPS
- CSBR 0.21
- ABOS N/A
- Revenue
- CSBR $56,878,000.00
- ABOS N/A
- Revenue This Year
- CSBR $9.30
- ABOS N/A
- Revenue Next Year
- CSBR $31.17
- ABOS N/A
- P/E Ratio
- CSBR $29.53
- ABOS N/A
- Revenue Growth
- CSBR 10.11
- ABOS N/A
- 52 Week Low
- CSBR $3.75
- ABOS $0.86
- 52 Week High
- CSBR $11.99
- ABOS $3.36
- Technical
- Relative Strength Index (RSI)
- CSBR 46.30
- ABOS 64.63
- Support Level
- CSBR $6.27
- ABOS $1.71
- Resistance Level
- CSBR $6.90
- ABOS $1.86
- Average True Range (ATR)
- CSBR 0.29
- ABOS 0.13
- MACD
- CSBR -0.02
- ABOS 0.05
- Stochastic Oscillator
- CSBR 23.37
- ABOS 76.56
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.